FDA pilot program allows generative AI medical devices to reach patients before formal authorization
Source Summary
The FDA has accepted four generative AI medical devices, including products from Cadence and Limbic, into its TEMPO pilot program. The pilot allows digital health companies to release products to patients without obtaining prior marketing authorization from the FDA.
Why it matters
The TEMPO pilot represents a regulatory pathway that accelerates patient access to AI-driven medical tools while bypassing traditional pre-market authorization requirements.
